The development and registration of topical pharmaceuticals

Area of Science:

• Pharmaceutical Sciences
• Dermatology
• Regulatory Affairs

Background:

• Topical drug delivery has advanced significantly over 60 years, with increased understanding of drug disposition in the skin.
• Pharmaceutical scientists now develop tailored dermatological vehicles, improving drug delivery, efficacy, and safety.
• While New Chemical Entity (NCE) topical development is understood, regulatory pathways for established Active Pharmaceutical Ingredients (APIs) in new topical formulations are less clear.

Purpose of the Study:

• To provide guidance on regulatory routes for European marketing approval of topical formulations.
• To clarify development pathways for established APIs in new topical formulations or concentrations.
• To offer insights into topical administration as an alternative route for known APIs.

Main Methods:

• Review of existing regulatory guidelines for topical drug products in Europe.
• Analysis of development pathways for both New Chemical Entities (NCEs) and established Active Pharmaceutical Ingredients (APIs).
• Emphasis on clinical development strategies for topical formulations.

Main Results:

• Clearer understanding of regulatory pathways for topical formulations is needed, particularly for established APIs.
• Guidelines for NCE topical development are relatively straightforward.
• Specific challenges exist for topical formulations of known APIs, including new formulations, concentrations, or alternative administration routes.

Conclusions:

• Navigating European regulatory pathways for topical formulations, especially those involving established APIs, requires detailed understanding.
• This article aims to demystify these routes, aiding pharmaceutical scientists in achieving marketing approval.
• Successful development hinges on appreciating formulation impacts on drug delivery, efficacy, and safety.